Safety, Efficacy, and Black Box Warnings: Challenges Associated With Off-Label Treatments of AAD
- Author
- ReachMD
- Published
- Tue 15 Oct 2024
- Episode Link
- http://reachmd.com/programs/cme/safety-efficacy-and-black-box-warnings-challenges-associated-with-off-label-treatments-of-aad/27099/
CME credits: 1.25
Valid until: 15-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/safety-efficacy-and-black-box-warnings-challenges-associated-with-off-label-treatments-of-aad/27099/
Valid until: 15-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/safety-efficacy-and-black-box-warnings-challenges-associated-with-off-label-treatments-of-aad/27099/
This series of bite-sized episodes contains important information on diagnosing and treating agitation in Alzheimer’s disease (AAD). Drs. Anton Porsteinsson and Brendan Montano discuss best practices for recognizing early symptoms, diagnosing patients, and treating their AAD.
